Eli Lilly and Company has broken ground on a new $5-billion manufacturing facility in Goochland County, Virginia, west of Richmond, Virginia, which will produce active pharmaceutical ingredients (APIs ...
The deeper threat to the biopharmaceutical industry may come not from macro-level disruption, but from structural pressures ...
How AI and other digital tools are progressing across the bio/pharmaceutical industry is on top of mind. Key perspectives on ...
Merck KGaA has agreed to acquire Silence Therapeutics, a Cambridge, UK-based clinical-stage bio/pharmaceutical company developing short interfering RNA (siRNA) medicines, for $1.3 billion, ...
Sanofi has broken ground on a new insulin manufacturing facility in Frankfurt, Germany. The new facility will be built on a 36,000-square-meter footprint at the Sanofi BioCampus in Frankfurt.
The Board of Directors of CSL, a Melbourne, Australia-based bio/pharmaceutical company, has appointed Deborah Waterhouse, currently Chief Executive Officer (CEO) of ViiV Healthcare, a joint venture ...
Welcome to the newest Member Companies in the Drug, Chemical & Associated Technologies Association (DCAT). DCAT is pleased to welcome the following companies to the DCAT Member Community. To view all ...
In looking at the news developments from the CDMO market in 2026, certain themes emerge. The blockbuster success of the glucagon-like peptide-1 (GLP-1) receptor agonists for treating obesity and Type ...
The bottom-line questions are what has been the impact on the performance of the bio/pharmaceutical industry, and what may be in store? How did the industry perform in 2025, and what can be expected ...
One way in which individual companies have responded to changing US trade policy is to emphasize their investments in US-based manufacturing and R&D activities. Thus far in 2025, many of the large bio ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results